CHRISTIE CHRISTOPHER 4

What Happened Christopher Christie, a director of Pacira BioSciences, received two equity awards on June 10, 2026: 6,405 restricted stock units (RSUs) and a derivative award representing 10,891 shares (a stock option). Both awards were recorded at $0.00 (no cash paid) and total 17,296 contingent share units. These are grants/awards rather than open-market purchases or sales.

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (timely filing).
• Awards: 6,405 RSUs (grant, $0.00) and 10,891-share derivative award (stock option, $0.00).
• Vesting/exercisable: RSUs vest June 10, 2027 if continuous service; the option vests/becomes exercisable June 10, 2027 if continuous service (see footnotes F1, F2).
• Shares owned after transaction: not reported in the provided filing details.
• No 10b5-1 plan, gifts, or tax-withholding actions noted in the provided information.

Context These awards are typical long-term compensation for directors and do not reflect an immediate market purchase or sale; RSUs convert to common shares at vesting and the option becomes exercisable only if Christie remains in service through June 10, 2027. Such grants are routine and intended for retention/compensation rather than an immediate bullish or bearish signal.